Healthcare and Life Science
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial Assay will be available as a service in the Babraham Institute’s F...
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
· Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics · Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases · ...
How to go Vegan For Veganuary
Plus a Vegan recipe: Quorn and Chickpea Stew
Cambourne Park Science & Technology Campus unveils new identity and welcomes first letting under new ownership
Rakon: Leading global precision timing designer and manufacturer chooses Cambourne Park Science & Technology Campus as location of choice for UK design hub. - Rakon secures 4,877 sq ft in Building 2020 with a ten year lease term. - New owner, Life Science REIT unveils new Campus ...
Seeking managers for research interviews on workplace wellbeing decisions
The UEA workplace wellbeing team calls for UK managers of any level, any sector, to take part in new research about decision-making on workplace wellbeing activities. ...
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness Dublin, Ireland, and Tampere, Finland - ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad...
Guardtech pledge to support NHS aseptic pharmacy units in 2024 after spike in enquiries
The Haverhill cleanroom construction experts have been inundated with enquiries from the nation’s healthcare heroes in recent months ...
Supporting a Phase III R&D strategy within the anti-infective space
Client Issue An emerging pharmaceutical company sought to evaluate Phase III development strategies for an anti-infective drug with potential to treat a range of patient populations. ...
Establishing real-world testing and treatment patterns for EGFR NSCLC patients
Client issue Oncology-focused biotech was looking to establish real-world testing and treatment patterns among EGFR NSCLC patients in US, EU, Japan, and Greater China (mainland, HK, and Taiwan). ...
Rare Disease: 2023 in Review
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings. In the last five years, our consultants have undertaken over 700 client projects in rare diseases, constituting over 20% of our...